Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Kouroukis, Tom
  • Chen, CI
  • White, D
  • Kouroukis, CT
  • Stewart, AK
  • Howson-Jan, K
  • Larratt, L
  • Powers, J
  • Eisenhauer, E

publication date

  • November 16, 2004

published in